ResultsIQ

ResultsIQ › Latest results › Molbio Diagnostics Limited

Molbio Diagnostics Limited Q1 FY27 earnings call summary

NSE: MOLBIO · BSE: 544866

Earnings call of 8 Sep 2026, summarised by AI from the filing.

Molbio Q1 FY27 revenue ₹408 cr, EBITDA ₹104 cr (25% margin), PAT ₹52.7 cr; guides 25% revenue growth and 24-25% EBITDA margin for FY27.

Key takeaways

  1. FY27 guidance Management guides roughly 25% top-line growth and 24% to 25% EBITDA margin this year.
  2. Export catch-up Export revenue ₹67 cr (16% of revenue) included catch-up of Q4 FY26 deferrals due to Gulf situation.
  3. Growth drivers HPV national program rollout, OptraScan US FDA clearance, and export expansion expected to drive growth.
  4. Key risk Business not linear quarter-on-quarter due to public health operations; OptraScan not profitable in FY27.

Original filing on BSE

Molbio Diagnostics Limited Q1 FY27 results

As filed: Revenue ₹399 cr, EBITDA ₹91.6 cr, PAT ₹56.6 cr, EBITDA margin 22.9%.

Not scored. No result for the same quarter last year.

Molbio Diagnostics Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.